Drug General Information
Drug ID	D0ZW5D
Former ID	DIB002070
Drug Name	LY-2409021
Synonyms	Oral glucagon receptor antagonist (type 2 diabetes), Eli Lilly
Indication	Type 2 diabetes [ICD9: 250; ICD10:E11]		Phase 2	[524685]
Company	Eli Lilly & Co
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	Glucagon receptor	Target Info	Antagonist	[533135]
KEGG Pathway	Neuroactive ligand-receptor interaction
	Glucagon signaling pathway
Reactome	Glucagon signaling in metabolic regulation
	G alpha (q) signalling events
	G alpha (s) signalling events
	Glucagon-type ligand receptors
WikiPathways	GPCRs, Class B Secretin-like
	Gastrin-CREB signalling pathway via PKC and MAPK
	Integration of energy metabolism
	GPCR ligand binding
	GPCR downstream signaling
References
Ref 524685	ClinicalTrials.gov (NCT02091362) A Study of LY2409021 on Blood Pressure and Pulse Rate in Participants With Type 2 Diabetes Mellitus. U.S. National Institutes of Health.
Ref 533135	Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes. Diabetes Obes Metab. 2015 Apr;17(4):414-22.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.